Back to Search
Start Over
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection
- Source :
- Cell Reports
- Publication Year :
- 2022
-
Abstract
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may target epitopes that reduce durability or increase the potential for escape from vaccine-induced immunity. Using synthetic vaccinology, we have developed rationally immune-focused SARS-CoV-2 Spike-based vaccines. Glycans can be employed to alter antibody responses to infection and vaccines. Utilizing computational modeling and in vitro screening, we have incorporated glycans into the receptor-binding domain (RBD) and assessed antigenic profiles. We demonstrate that glycan-coated RBD immunogens elicit stronger neutralizing antibodies and have engineered seven multivalent configurations. Advanced DNA delivery of engineered nanoparticle vaccines rapidly elicits potent neutralizing antibodies in guinea pigs, hamsters, and multiple mouse models, including human ACE2 and human antibody repertoire transgenics. RBD nanoparticles induce high levels of cross-neutralizing antibodies against variants of concern with durable titers beyond 6 months. Single, low-dose immunization protects against a lethal SARS-CoV-2 challenge. Single-dose coronavirus vaccines via DNA-launched nanoparticles provide a platform for rapid clinical translation of potent and durable coronavirus vaccines.<br />Graphical abstract<br />Glycan engineering of immunogens is a key vaccine design strategy to focus antibodies to select epitopes. Konrath et al. create an automated pipeline to screen SARS-CoV-2 RBD for PNGS. PNGS-modified RBDs elicit enhanced ACE2-directed responses and higher neutralization. Multivalent display of glycan-engineered RBDs delivered via nucleic acid provides single-dose protection from challenge.
- Subjects :
- COVID-19 Vaccines
Guinea Pigs
computational design
General Biochemistry, Genetics and Molecular Biology
Article
RBD
Epitopes
Mice
Immunogenicity, Vaccine
Polysaccharides
immune-focusing
Cricetinae
vaccine
Animals
Vaccine Potency
SARS-CoV-2 Challenge
Binding Sites
SARS-CoV-2
nanoparticle
COVID-19
spike
Antibodies, Neutralizing
structure-based design
Spike Glycoprotein, Coronavirus
Nanoparticles
glycans
Nucleic Acid-Based Vaccines
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Cell Reports
- Accession number :
- edsair.doi.dedup.....b1496ef22157f363267c3a7c8c0b6c07